Cytogent

Resistant cancer · One network

The intelligence layer for resistant cancer.

When cancer stops responding to treatment, every week counts. Cytogent gives every patient an intelligent agent that watches their journey, and connects hospitals with the drug developers working on what comes next.

Member of the NVIDIA Inception Program.
  • Patient-Level Agents
  • Tumour-board preparation
  • Trial options
  • Anonymised insight
  • Study requests
  • Built for resistance
  • European by design
  • Data stays in the hospital

01The problem in three numbers

The science is moving. The connection is not.

See every number and its source

Each cell is one in a hundred

02The network

One platform.
Two sides. One goal.

  • For hospitals and clinicians

    See resistance coming.

    • A Patient-Level Agent for every enrolled patient
    • Important changes flagged early
    • Resistance anticipated before it surprises you
    • Tumour-board documents prepared for you
    • Trial options found for every willing patient
  • For drug developers and researchers

    Find the right patients, earlier.

    • Live insight into resistant-cancer populations
    • Recommendations on what to study next
    • Groups of patients ready for your study
    • Forecasts of who will be eligible, where and when
    • Apply to hospitals directly, with your full offer

03How it works

Connect. Understand. Act.

Three steps, no heavy lifting for your team.

See the platform
  1. 01Inside the hospital

    Connect

    Cytogent connects securely to the hospital’s records. Data stays inside the hospital.

  2. 02One agent per patient

    Understand

    Every enrolled patient gets a Patient-Level Agent that follows their care and learns from the care team.

  3. 03Insight to action

    Act

    Clinicians get timely insight and trial options. Drug developers get the right patients and a clear next step.

Your expertise leads. Cytogent makes sure nothing is missed.

04Why Cytogent

Built for the moment treatment stops working.

  • Built for resistance

    Not a general tool. Designed around the moment treatment stops working.

  • Learns from real practice

    Every review by a clinician makes the system smarter for the next patient.

  • Sees ahead

    We don’t only show who is eligible today; we anticipate who will be.

  • Neutral and European

    Independent of any drug company or test lab, built for European privacy rules.

05Trust

Patient data never leaves the hospital without permission.

Sponsors see anonymised insight, never identities. Clinicians decide; Cytogent supports.

  • Data stays in the hospital
  • Anonymised insight only
  • European privacy rules
  • The clinician decides

Founding network · Europe

Join the network that puts resistant cancer first.

We are onboarding a founding group of cancer centres and research partners in Europe.

Questions

Quick answers.

What is Cytogent?

Cytogent is the intelligence layer for resistant cancer. It connects hospitals and drug developers around the moment a cancer stops responding to treatment: a Patient-Level Agent for every enrolled patient, and anonymised insight for the teams developing what comes next.

How the platform works

Who is Cytogent for?

Two sides of one network. Hospitals and clinicians who care for people with resistant cancer, and pharma, biotech, university and research teams who develop the therapies and studies that come next.

Does Cytogent replace clinical judgement?

No. The clinician always decides. Cytogent supports the care team by surfacing what matters, preparing documents and finding options.

Where does patient data go?

Patient data stays inside the hospital. Sponsors see anonymised insight, never identities, and contact with patients happens only through their own clinicians and with consent.

How we protect data

How do I join?

Tell us who you are on the Join page. We reply within two working days, set up a 30-minute call and walk you through the platform.

Join Cytogent